Why the study?
Does tamoxifen 20 mg/day alter the risk of cardiovascular events in women at increased risk for breast cancer with or without prior CHD?
Population
13,388 women at increased risk for breast cancer
Comparison
Tamoxifen 20 mg/day vs Placebo
Design
RCT, randomly assigned
Follow-up
mean 49 months
Authors
Loading...
Affirms cardiovascular safety of tamoxifen for breast cancer prevention; confirms neutrality on events in RCT data regardless of CHD status.
Does tamoxifen 20 mg/day alter the risk of cardiovascular events in women at increased risk for breast cancer with or without prior CHD?
Tamoxifen used for breast cancer prevention does not significantly increase or decrease the risk of cardiovascular events, regardless of baseline CHD status.
Reís et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: